CREATE, formerly Myeloid Therapeutics, disclosed preclinical in vivo CAR-T/CAR-NK and all-RNA RetroT work at AACR 2026. Clinical MT-302 is a myeloid-cell program, not evidence that its CAR-T programs have reached the same stage. The former name is retained as an alias.
Closed financing announced by company; not a cumulative funding total.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
CREATE, formerly Myeloid Therapeutics, disclosed preclinical in vivo CAR-T/CAR-NK and all-RNA RetroT work at AACR 2026. Clinical MT-302 is a myeloid-cell program, not evidence that its CAR-T programs have reached the same stage. The former name is retained as an alias.
Program / service
Target / indication
Representative stage
Evidence & scope
RetroT / multi-immune CAR
See program source; distinguish indications
Preclinical
No human CAR-T evidence verified in this review.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
CREATE Medicines entered a research collaboration and license agreement with WestGene to combine immune-cell programming and RNA gene-writing technologies with targeted lipid nanoparticles. Initial work spans three in vivo CAR programs involving autoimmune disease, solid tumors, and durable gene expression. The partnership expands delivery access and development options, but the announcement does not demonstrate clinical efficacy of the combined approaches.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
CSPC announced initiation of the first Chinese center for SYS6055-003, a Phase 1/2 trial in relapsed or refractory B-cell non-Hodgkin lymphoma. SYS6055 uses lentiviral vectors to generate CD19-targeting CAR-T cells in vivo. The company said recruitment and screening are underway following October clinical-trial authorization. Center initiation does not establish patient dosing, efficacy, or marketing approval.
Azalea reported SITC preclinical findings for its dual-vector in vivo CAR-T platform, combining targeted CRISPR-Cas9 delivery with AAV-mediated CAR insertion at the TRAC locus. The company described leukemia clearance and protection after tumor rechallenge in selected mouse groups, plus dual-antigen and armored designs. These are animal findings, not evidence of efficacy or safety in patients.
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
